TY - JOUR
T1 - Analysis of polypharmacy effects in older patients using Japanese adverse drug event report database
AU - Abe, Junko
AU - Umetsu, Ryogo
AU - Uranishi, Hiroaki
AU - Suzuki, Honami
AU - Nishibata, Yuri
AU - Kato, Yamato
AU - Ueda, Natsumi
AU - Sasaoka, Sayaka
AU - Hatahira, Haruna
AU - Motooka, Yumi
AU - Masuta, Mayuko
AU - Nakamura, Mitsuhiro
N1 - Funding Information:
This research was partially supported by JSPS KAKENHI grant number 17K08452.
Publisher Copyright:
© 2017 Abe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2017/12
Y1 - 2017/12
N2 - Population aging is a global phenomenon, and choosing appropriate medical care for the elderly is critical. Polypharmacy is suspected to increase the risk of adverse events (AEs) in older patients. We examined the AE profiles associated with polypharmacy and aging using the Japanese Adverse Drug Event Report (JADER) database. We attempted to mitigate the effect of patient-related factors using a multiple-logistic regression technique and data subsetting. We selected case reports for AEs as specified in the Medical Dictionary for Regulatory Activities (MedDRA). The association between polypharmacy and “renal disorder” or “hepatic disorder” was evaluated using reporting odds ratio (ROR) and adjusted for covariates using multiple-logistic regression. For renal disorder, advanced polypharmacy showed higher adjusted RORs, because the value of administered drugs group [1.82 (1.76–1.88), ≥10] was higher than that of the number of administered drugs group [1.27 (1.24–1.31), 5–9]. The lower limit of the 95% confidence interval (CI) of adjusted ROR for age ( ≥60 years) was > 1 for renal disorder. For hepatic disorder, the adjusted RORs were as follows: 1.17 (1.14–1.20) for the number of administered drugs group (5–9) and 1.14 (1.11–1.18) for the number of administered drugs group ( ≥10). The adjusted RORs of hepatic disorder compared to those of renal disorder had lower adjusted RORs related to the increase in the number of administered drugs. Therefore, elderly individuals should be closely monitored for the occurrence of renal disorder when they are subjected to polypharmacy. This approach might apply to the simultaneous evaluation of the AE risk of polypharmacy and aging.
AB - Population aging is a global phenomenon, and choosing appropriate medical care for the elderly is critical. Polypharmacy is suspected to increase the risk of adverse events (AEs) in older patients. We examined the AE profiles associated with polypharmacy and aging using the Japanese Adverse Drug Event Report (JADER) database. We attempted to mitigate the effect of patient-related factors using a multiple-logistic regression technique and data subsetting. We selected case reports for AEs as specified in the Medical Dictionary for Regulatory Activities (MedDRA). The association between polypharmacy and “renal disorder” or “hepatic disorder” was evaluated using reporting odds ratio (ROR) and adjusted for covariates using multiple-logistic regression. For renal disorder, advanced polypharmacy showed higher adjusted RORs, because the value of administered drugs group [1.82 (1.76–1.88), ≥10] was higher than that of the number of administered drugs group [1.27 (1.24–1.31), 5–9]. The lower limit of the 95% confidence interval (CI) of adjusted ROR for age ( ≥60 years) was > 1 for renal disorder. For hepatic disorder, the adjusted RORs were as follows: 1.17 (1.14–1.20) for the number of administered drugs group (5–9) and 1.14 (1.11–1.18) for the number of administered drugs group ( ≥10). The adjusted RORs of hepatic disorder compared to those of renal disorder had lower adjusted RORs related to the increase in the number of administered drugs. Therefore, elderly individuals should be closely monitored for the occurrence of renal disorder when they are subjected to polypharmacy. This approach might apply to the simultaneous evaluation of the AE risk of polypharmacy and aging.
UR - http://www.scopus.com/inward/record.url?scp=85038955149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038955149&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0190102
DO - 10.1371/journal.pone.0190102
M3 - Article
C2 - 29267348
AN - SCOPUS:85038955149
VL - 12
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 12
M1 - e0190102
ER -